Products

OssiFi combines the novelty of its targets and therapeutic approach with well-established technologies to rapidly and efficiently bring product candidates into clinical development. OssiFi has expertise and infrastructure in several critical areas such as small molecule development, protein engineering, preclinical efficacy, pharmacology and GMP manufacturing. Our R&D approach is exceptionally productive and is the basis for our rich pipeline of product candidates.

OssiFi applies its unique insight to develop novel therapeutics to modulate the growth of bone. OssiFi is establishing itself as the premier company in the field of therapeutics based on the Sclerostin/Wnt family.

Other attempts to capitalize on the therapeutic promise of the sclerostin family were based on the concept of inhibiting a BMP inhibitor to achieve the desired therapeutic effect. This strategy has not produced candidates.

OssiFi is taking a fundamentally different approach to harness the power of the Sclerostin family. Rather than inhibit a BMP inhibitor, our approach is to inhibit the WNT activity of sclerostin to achieve our desired therapeutic outcome, which allows WNT to act at psychological levels. In situations in which we seek to increase tissue strength, such as bone in osteoporosis, our approach is to inhibit negative regulators of tissue growth. By inhibiting the negative regulators of tissue growth, we allow the naturally occurring growth factors to increase bone strength. 

OssiFi uses proven therapeutic technologies to rapidly and efficiently design and develop its small molecule therapeutics. This approach significantly reduces the technical risk, improve cycle times, capitalize on established regulatory guidelines and physician familiarity with the types of compounds we develop. All of these benefits allow us to improve the probability of creating drugs that will dramatically improve the lives of the patients who will receive our drugs.